Peripheral Vascular Diseases Clinical Trial
Official title:
GORE VIABAHN Endoprosthesis Versus Bare Nitinol Stent in the Treatment of Long Lesion (>8cm) Superficial Femoral Artery Occlusive Disease
Verified date | May 2012 |
Source | W.L.Gore & Associates |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
To evaluate the performance of the GORE VIABAHN® Endoprosthesis compared to a bare nitinol stent for the treatment of superficial femoral artery (SFA) occlusive disease in long lesions.
Status | Completed |
Enrollment | 148 |
Est. completion date | January 2011 |
Est. primary completion date | January 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: - Lifestyle-limiting claudication or rest pain. - Subject (or their legal guardian) has read, understood and provided written informed consent. - At least 21 years of age. - Quality of life questionnaires completed. - Noninvasive lower extremity arterial studies within 45-days prior to study procedure. - If applicable, staged ipsilateral vascular procedure = 14-days prior to study procedure. - If applicable, vascular treatment on non-study leg for bilateral claudication = 14-days prior to study procedure. - Male, infertile female, or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test. - Projected life expectancy of greater than three years. - The ability to comply with protocol. - Angiographic and Lesion Requirements meets protocol criteria. Exclusion Criteria: - Untreated flow-limiting aortoiliac occlusive disease. - Any previous stenting or surgery in the target vessel. - Subjects with arterial lesions requiring treatment with device diameters other than 6, 7, or 8 mm. - Severe ipsilateral common femoral/profunda disease requiring surgical intervention. - Femoral or popliteal aneurysm. - Non-atherosclerotic disease resulting in occlusion. - Tibial artery disease requiring treatment. - Prior ipsilateral femoral artery bypass. - Severe medical comorbidities. - Popliteal artery vascular access at any time during procedure. - Antegrade and retrograde vascular access on the same common femoral artery at the time of the SFA intervention. - Serum creatinine > 2.5 mg/dL within 45 days prior to study procedure. - Major distal amputation. - Septicemia. - Any previously known coagulation disorder. - Morbid obesity or operative scarring that precludes percutaneous approach (physician's discretion). - Contraindication to anticoagulation or antiplatelet therapy. - Known allergies to stent/stent-graft components. - History of prior life-threatening reaction to contrast agent. - Currently participating in another clinical research trial. - Current peritoneal or hemodialysis. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Vascular Surgical Associate | Austell | Georgia |
United States | Heritage Valley Health Systems | Beaver | Pennsylvania |
United States | The Cleveland Clinic Foundation | Cleveland | Ohio |
United States | Midwest Cardiology Research Foundation | Columbus | Ohio |
United States | Holy Cross Hospital | Ft Lauderdale | Florida |
United States | Arkansas Heart | Little Rock | Arkansas |
United States | Midwest Heart Foundation | Lombard | Illinois |
United States | Midwest Institute for Minimally Invasive Therapy | Melrose Park | Illinois |
United States | St Luke's Medical Center | Milwaukee | Wisconsin |
United States | Ochsner Clinic | New Orleans | Louisiana |
United States | St Francis Medical Center | Peoria | Illinois |
United States | Mayo Clinic Phoenix | Phoenix | Arizona |
United States | Allegheney General Hospital | Pittsburgh | Pennsylvania |
United States | St. Johns Hospital/Prairie Education Research | Springfield | Illinois |
United States | Washington University | St Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
W.L.Gore & Associates |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy: Primary Patency at Three Years | Primary patency is the Peak Systolic Velocity Ratio (PSVR) maintained at or below 2.0 without any repeat intervention. The PSVR is the ratio of the highest velocity (or pressure) of the blood moving through the stent divided by the velocity immediately outside the stent (the end of the stent nearest to the heart). Pressures are measured by ultrasound. These results include the percentage of subjects that maintained primary patency at or below 2.0 without any repeat intervention through the end of the study (three years). |
3 years | No |
Primary | Safety: Composite of Major Procedural (30-day) Adverse Events (AEs) | Major procedural events include death, myocardial infarction, acute renal insufficiency, study limb amputation, and access site and treatment site complications requiring surgery or blood transfusion. The results for this outcome measure are the total percent of these events that occurred in each treatment arm within the first 30 days following stent implantations. | 30 days | Yes |
Secondary | Primary Assisted Patency | Primary assisted patency is defined as when the subject had a repeat intervention to regain patency in order to salvage the stent prior to complete occlusion. | 3 years | No |
Secondary | Secondary Patency | Secondary patency is defined as maintaining patency in the target vessel after a repeat intervention to correct complete occlusion in the treated arterial segment. | 3 years | No |
Secondary | Technical Success at Initial Procedure | Technical success is defined as a composite of both a) restoration of superficial femoral artery (SFA) patency with < 30% residual stenosis (narrowing) within the treated arterial segment as viewed on post-procedure completion angiography, and b) Final Hemodynamic Pressure Gradient =15mm Hg (mercury). A lower pressure gradient number indicates less resistance to blood flow; i.e., less stenosis or narrowing of the vessel under the pressure of the flow. The results show the percentage of study subjects that had technical success. |
Time of implant procedure | No |
Secondary | Target Vessel Revascularization (TVR) | This measure shows the percentage of subjects that had at least one repeat intervention performed during their enrollment in the clinical study. | 3 years | No |
Secondary | Target Lesion Revascularization (TLR) | This measure shows the percentage of subjects that had at least one repeat intervention in the target lesion during their enrollment in the clinical study. | 3 years | No |
Secondary | Improvement in Rutherford Classification (Clinical Success) | The Rutherford Classification is a system used to score Peripheral Artery Disease (PAD). The stages follow (higher numbers are worse): Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene The percentage of people improving by at least one stage (moving frm higher number to lower number) is listed in the results. |
3 years | No |
Secondary | Quality of Life Subject Self-assessments (Intermittent Claudication Questionnaire: ICQ) (Clinical Success) | The ICQ is a series of 16 questions asking about leg pain and limitations to activities such as walking specific distances, doing daily activities, worrying about pain, resting during activities, and similar. Most questions specifically ask about only the two weeks prior to answering the completion of the questionnaire. Improvement in Intermittent Claudication Questionnaire (ICQ) is a lower score (0 = best, 100 = worst). A decrease in mean score from baseline indicates an improvement in the patient's condition and an increase indicates a decline. |
3 years | No |
Secondary | Quality of Life Subject Self-assessments (Short Form:36 (SF:36) - Mental Summary Score)) (Clinical Success) | The SF-36 Health Survey (version 2) asks 36 questions to measure health and well-being from the patient's point of view. The subscale and total score ranges from 0 to 100 but is normalized so that a score of 50 is the population mean, with a standard deviation of 10. The SF:36 - Mental Summary Score Questionnaire score must improve in order to be considered for clinical success. An increase in the mean score from baseline indicates an improvement in the patient's condition and a decrease indicates a decline. |
3 years | No |
Secondary | Quality of Life Subject Self-assessments (Short Form:36 (SF:36) - Physical Summary Score)) (Clinical Success) | The SF-36 Health Survey (version 2) asks 36 questions to measure health and well-being from the patient's point of view. The subscale and total score ranges from 0 to 100 but is normalized so that a score of 50 is the population mean, with a standard deviation of 10. The SF:36 - Physical Summary Score Questionnaire score must improve in order to be considered for clinical success. An increase in the mean score from baseline indicates an improvement in the patient's condition and a decrease indicates a decline. |
3 years | No |
Secondary | Change in Ankle-Brachial Index (ABI) | This test is done by measuring blood pressure at the ankle and the arm while a person is at rest. The ABI is then calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm. A normal resting ABI is 0.9 to 1.3. A resting ABI of less than 0.9 is abnormal. An outcome of a higher mean ABI is considered a success. |
3 years | No |
Secondary | Alternate Peak Systolic Velocity Ratio (PSVR) (Equal or Less Than 2.5) | The PSVR is the ratio of the highest velocity (or pressure) of the blood moving through the stent divided by the velocity immediately outside the stent (the end of the stent nearest to the heart). Pressures are measured by ultrasound. These results include the percentage of subjects that had a PSVR of equal or less than 2.5. | 3 years | No |
Secondary | Alternate Peak Systolic Velocity Ratio (Less Than or Equal to 3.0) | The PSVR is the ratio of the highest velocity (or pressure) of the blood moving through the stent divided by the velocity immediately outside the stent (the end of the stent nearest to the heart). Pressures are measured by ultrasound. These results include the percentage of subjects that had a PSVR of equal or less than 3.0. | 3 years | No |
Secondary | Occurrence of Stent Fracture | The outcome of stent fracture measures the percentages of subjects that had stent fractures, as observed in their 1yr follow-up visit X-rays. | 1 year | No |
Secondary | Occurrence of Stent Fracture | The outcome of stent fracture measures the percentages of subjects that had stent fractures, as observed in their 2yr follow-up visit X-rays. | 2 years | No |
Secondary | Occurrence of Stent Fracture | The outcome of stent fracture measures the percentages of subjects that had stent fractures, as observed in their 3yr follow-up visit X-rays. | 3 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Completed |
NCT00536796 -
Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
|
N/A | |
Completed |
NCT00371371 -
Intra-arterial Stem Cell Therapy for Patients With Chronic Limb Ischemia (CLI)
|
Phase 1/Phase 2 | |
Recruiting |
NCT00173602 -
The Burden of Peripheral Artery Occlusion Disease and Associated Factors in Peritoneal Dialysis Patients
|
N/A | |
Completed |
NCT00163267 -
Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel
|
Phase 2/Phase 3 | |
Completed |
NCT00106327 -
Improving Functioning in Peripheral Arterial Disease
|
N/A | |
Completed |
NCT00049907 -
Cardiac and Renal Disease Study (CARDS)
|
N/A | |
Completed |
NCT00000614 -
Prevention of Recurrent Venous Thromboembolism (PREVENT)
|
Phase 3 | |
Completed |
NCT00005392 -
Epidemiology of Venous Disease
|
N/A | |
Recruiting |
NCT05596760 -
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
|
N/A | |
Recruiting |
NCT00539266 -
Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia
|
Phase 2/Phase 3 | |
Completed |
NCT00541307 -
GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)
|
N/A | |
Completed |
NCT00520312 -
Magnetic Resonance Imaging to Identify Characteristics of Plaque Build-Up in People With Peripheral Arterial Disease
|
N/A | |
Terminated |
NCT00504088 -
Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia
|
Phase 4 | |
Completed |
NCT00533104 -
Cell Therapy in Chronic Limb Ischemia
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05459818 -
Individual Patient Data Analysis of Viabahn for Peripheral Arterial Disease
|
||
Completed |
NCT03875846 -
Intraoperative Simultaneous Pressure Guided Revascularization Study
|
||
Active, not recruiting |
NCT05110677 -
Pilot Study of Topographic Imaging of the Calf Muscle in Patients With PAD Using 3D Reconstruction of MSOT Images
|
||
Active, not recruiting |
NCT02856230 -
An Efficacy and Safety Study to Evaluate Ranger DEB for BTK Angioplasty in Patients With CLI (RANGER-BTK)
|
Phase 2/Phase 3 | |
Completed |
NCT01014377 -
Effect of VascuActive Device on Foot Perfusion, Hemodynamics and Exercise Capacity in Patients With PVD & Limb Ischemia
|
N/A |